BDX · Becton Dickinson & Co
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Free Cash Flow non-GAAP | $1,728M | Nine Months Ended June 30, 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BDX
this stock
Becton Dickinson & Co
|
$48.23B | +17.6% | +8.2% | 88.5 | 3.8% |
|
ISRG
Intuitive Surgical Inc
|
$132.02B | -34.0% | +20.5% | 42.9 | 1.9% |
|
MDLN
Medline Inc.
|
$45.37B | -17.8% | +11.5% | — | 2.2% |
|
ALC
Alcon Inc
|
$33.91B | -11.3% | +10.5% | — | 2.7% |
|
RMD
Resmed Inc
|
$32.38B | -6.8% | +13.4% | 21.5 | 9.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BDX | +7.0% | +17.4% | +0.9% | +6.9% | +17.6% |
| SPY | +3.6% | +2.2% | +12.8% | +2.9% | +12.7% |
| vs SPY | +3.4% | +15.1% | -11.9% | +4.0% | +4.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.